Johnson & Johnson defied generic competition to post positive Q3 figures, including increases to both turnover and worldwide pharmaceutical sales.
Turnover rose 6.8% to approximately $16bn, whereas worldwide pharmaceutical sales increase 8.9% to $5.98bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company’s biggest earner continued to be anti-inflammatory Remicade, with sales witnessing a 14.6% increase to $1.41bn.
The detrimental effect of generic competition wasn’t completely unfelt, however, as group net earnings fell 6.3% to $3.2bn and US sales fell 6.1%, with domestic sales of antipsychotic medication Risperdal only totalling $8m.
J&J’s Topamax and Procrit / Eprex medications also suffered at the hands of generics, with sales falling by 7.9% and 5.7% respectively.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
